

Rapid Communication

Determination of IgG Response Profile in SARS-CoV-2 Patients Using a Multiplex Serological Assay

Brochot E^{1,2*}, Souplet V^{3*}, Follet P³, Ponthieu P³, Olivier C³, Even G⁴, Audebert C⁴ and Malbec R⁴

¹Department of Virology, Amiens University Medical Center, Amiens, France

²Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France

³Innobiochips, 70 rue du Dr Yersin, 59120 Loos, France

⁴GD Biotech, 3595 Route de Tournai, 59501 Douai, France

*Corresponding author: Etienne Brochot,

Department of Virology, Amiens University Medical Center, Amiens, France; Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France

Vianney Souplet, Innobiochips, 70 rue du Dr Yersin, 59120 Loos, France

Received: April 16, 2021; Accepted: May 11, 2021;

Published: May 18, 2021

Abstract

Background: Beyond the diagnosis of SARS-CoV-2 infection, tools delivering a global picture of the patients' humoral response may be of interest for the comprehension of the disease severity and the assessment of the patients' protection for vaccination strategy.

Objectives: Here we use a commercial multiplex serological immunoassay CoViDiag®, based on an array of five different antigens of the virus (the Nucleocapsid, the Spike 1 and Spike 2 subunits, and the RBD and NTD domains of the Spike), to investigate the profile of the IgG humoral response for patients with recent SARS-CoV-2 infection depending on the disease severity outcome, or the time post-PCR.

Results: No cross-reaction was observed with the four other seasonal coronaviruses (100% specificity, 0/28). 100% (20/20) of the hospitalized patients PCR-positive to SARS-CoV-2 presented detectable levels of IgGs. 14 days post-PCR diagnosis, 92.3% of the patients, PCR-positive, that did not require hospitalization are presenting IgG (36/39). Interestingly for CoViDiag-positive samples, detectable levels of anti-RBD were found mainly in hospitalized patients (85%, 17/20), while the presence of anti-S1 (60.9%, 28/46) combined with the absence of anti-RBD (6.5%, 3/46) was more characteristic of non-hospitalized patients. Screening campaign group lacked both anti-S1 (18.2%, 4/22) and anti-RBD (4.5%, 1/22).

Conclusion: The CoViDiag® IgG assay could be used to evaluate patients' immunization and improve their management.

Keywords: SARS-CoV-2; COVID-19; Serological assays; Multiplexing; IgG profile

Background

Since its first detection in Wuhan (China) in December 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread to reach other countries worldwide as the coronavirus 2019 disease (COVID-19) became pandemic [1]. SARS-CoV-2 is spreading through human-to-human contact and can cause respiratory infections among others illness. The clinical picture is very diverse, from asymptomatic infections of healthy carriers, which will increase the disease spreading, to fever, dry cough, breathing difficulties, headache, or pneumonia which make it difficult to differentiate from other respiratory diseases such as flus or human Coronaviruses (hCoVs). Moreover, if most cases are classified as mild (no or moderate signs) in the first stage of the disease, it can rapidly evolve to more severe and critical states and even cause death.

The virions has a nucleocapsid composed by genomic RNA and phosphorylated Nucleocapsid (N) protein, which is buried inside a phospholipid bilayer and covered by the Spike proteins trimmers (S) that gives the CoVs their crown-like appearance on which their names are based. The S protein has two subunits, the Spike 1 (S1) which contains the Receptor-Binding Domain (RBD) and N-Terminal Domain (NTD) and the Spike 2 (S2) [2]. The choice of the antigenic domain is important, as it must be specific

to the SARS-CoV-2 for discrimination against other hCoVs for example, and sensitive enough so infection would not be missed [3]. Most commercial serological assays have demonstrated satisfying performances in terms of diagnostic sensitivity and specificity, based on one of those main different antigenic domains [4,5]. It is now generally admitted that severe form of the disease are often associated to excessive immune response and "cytokine storms" [6]. However, kinetics of antibody response and protection efficiency remains poorly understood, especially several months after infection [4,7].

Objectives

The combination of different antigens could give a more comprehensive picture of the humoral response strength and diversity [8-10]. Thus, this study evaluates the immune profiling performances of the commercial multiplex immunoassay CoViDiag® targeting IgG antibodies against the N, S1, S1-RBD, S1-NTD, and S2 antigens (Figure 1), and its prognosis potential by investigating antibody patterns based on the time post-infection and the disease severity.

Material and Methods

Study design and cohort

The study was conducted at Amiens University medical Center




Figure 1: Full well pictures obtained with the microplate reader (SciReader®) or with a phone camera (in insert) after incubation with the CoViDiag® assay. A) Positive sample presenting antibodies against the Nucleopcapside (N), Spike 1 (S1), N-Terminal Domain (NTD) and Receptor Binding Domain (RBD) of the Spike protein, or Spike 2 (S2) antigens. B) Negative sample with positive control on the edges. Scale bars correspond to 1mm.

(France). Samples were derived from de-identified excess serum specimens as described in a previous study (Brochot et al., 2020b). The demographic information of the 167 patients are available in Supplementary Table 1. The study was approved by the institutional review board of the Amiens University Medical Center (number PI2020_843_0046, 21 April 2020).

Briefly n=167 sera samples from patients PCR-positive to SARS-CoV-2 and hospitalized (n=20), non-hospitalized patients but PCR-positive to SARS-CoV-2 (n=57), patients participating in screening campaigns (n=62), and a control group of patients with a history of other seasonal coronavirus infection (n=28) before 2020. Sera from patients PCR-positive to SARS-CoV-2 were collected between 0 to 80 days post-PCR.

All samples have been tested on the CoViDiag® serological assay and compared to the results obtained with three other IgG assays widely used worldwide (Euroimmun®, Abbott® and Diasorin®) [4].

CoViDiag® assay and analysis

The assays have been performed according to the manufacturer instructions. The results have been automatically delivered using the SciReader® plate reader (Scenion GmbH) and associated analysis software, and an algorithm combining different cut-offs for the different antigens according to the manufacturer instructions (Supplementary Table 1).

Data and statistical analysis

The demographic information of the 167 patients has previously been described [4].

Diagnostic specificity was evaluated on samples PCR-negative to SARS-CoV-2 but PCR-positive to other hCoVs. Diagnostic sensitivity was evaluated on samples PCR-positive to SARS-CoV-2 collected between 0 to 80 days post-PCR from hospitalized or non-hospitalized patients.

For the statistical analysis, Generalized Additive Models (GAM) were used to calculate Odds Ratios (OR) and 95% Confidence Interval (CI) considering positivity/negativity for CoViDiag, N, S1, S2, NTD and RBD as the main outcomes (borderline results have been filtered for group to group comparison) and controlling for personal background effects (sex and age). No influence of the delay between PCR and serology has been observed. The general

significance level was set at a p-value below 0.05. All analyses were performed using packages stats and odds ratio from the R statistical computing program v. 3.6.1 (Date of release 07/05/2019). Specifically, we compare the antibody response profile between patients group and depending on the time post-PCR to test whether a significant difference is present among different group variables.

Results

Diagnostic performances of the multiplex CoViDiag® IgG assay

All patients hospitalized for COVID-19 with a positive nasopharyngeal SARS-CoV-2 PCR were positive to the CoViDiag® IgG assay (n=20/20, 100%) (Table 1). We observed that only 80.7% of the patients with a positive SARS-CoV-2 PCR that did not require hospitalization were positive to the CoViDiag® IgG assay (n=46/57). The part of patients presenting IgG increases to 92.3% for samples collected at least 14 days after a positive PCR (n=36/39). We found 35.5 % of the patients participating in the screening campaigns positives to the CoViDiag® IgG assay (n=22/62). Using the CoViDiag® assay, we observed that 25.8% (n=16/62) of the patients from the screening campaign were lacking either the anti-N, anti-S1 or anti-S2 antibodies. Similar incomplete response was observed for 31.6% (n=18/57) of the non-hospitalized patients, and 10% of the





Figure 2: IgG profile of CoViDiag-positive patients: percentage of patients, positives to the CoViDiag assay, and with detectable levels of anti-N, anti-S1, anti-NTD, anti-RBD, and anti-S2 antibodies, depending on the disease outcome severity.

Table 1: Diagnostic performances of the CoViDiag® and three other commercial IgG serological assays. Diagnostic sensitivity and specificity observed for different patient groups: PCR-positive-hospitalized patients, PCR-positive-non-hospitalized patients, patients from screening campaign, and patients from control group PCR-positive to other hCoVs.

Assay name		CoViDiag®		Eurolmmune®		Diasorin®		Abbott®	
Type of immunoglobulins		IgG		IgG		IgG		IgG	
Antigen		N, S1, RBD, NTD,S2		S1		S1/S2		N	
Patient's group		Number of patients	Diagnostic Sensitivity	Diagnostic Sensitivity	Diagnostic Sensitivity	Diagnostic Sensitivity	Diagnostic Sensitivity	Diagnostic Sensitivity	Diagnostic Sensitivity
PCR positive	Hospitalized	20	100%	-	100%	-	100%	-	100%
	Non-hospitalized	57	80.70%	-	77.20%	-	70.20%	-	80.70%
Screening Campaigns		62	35.50%	-	37.10%	-	21%	-	29%
hCoV control group (before 2020)		28	-	100%	-	96.40%	-	100%	-



hospitalized ones (n=2/20). Among the 57 non-hospitalized patients, five presented only anti-S2 IgG (see supplementary Table 1). Among the 62 screening campaign patients, four presented only anti-S2, two only anti-N, and one only anti-NTD antibodies, highlighting the interest of targeting a wide scope of antibodies especially in the light form of the disease. There was no cross reactivity with the samples from patients PCR positive to other seasonal coronaviruses (OC43, HKU1, NL63, 229E), collected between day 7 and day 1153 post PCR (100 % diagnostic specificity, n=0/28).

Profile of the IgG antibody responses depending on the disease severity

For the patients presenting a positive IgG response to CoViDiag®, we find different profile of the immune response between the different patient groups (Figure 2). 95% (n=19/20) of the patients hospitalized presented anti-S1 IgG against 60.9% (n=28/46) of the patients non-hospitalized and 18.2% (n=4/22) of the patients from the screening campaign. Furthermore 85% (n=17/20) of the patients hospitalized presented anti-RBD IgG against 6.5% (n=3/46) of the patients non-hospitalized. The comparison of odds ratio for each antigen (Supplementary Table 2) confirmed that the presence of anti-RBD antibodies is the best marker for the chance of being in the hospitalized group versus non-hospitalized group (OR: 4.508, CI: 4.332-4.693, p-value: 7.34e-13) or screening campaign group (OR: 4.665, CI: 4.739-4.592, p-value: 2.48e-12). The presence of anti-S1 antibodies is the best marker for the chance of being in the non-hospitalized group versus screening campaign group (OR: 1.901, CI: 2.044-1.767, p-value: 0.002).

Profile of the IgG antibody responses depending on the time post-PCR

For the two groups of patients PCR positive to SARS-CoV-2, we investigated the profile of the IgG antibody responses depending on the delay between PCR and serology. Independently of the period of collection between 0 and 80 days post-PCR the majority of hospitalized patients presented detectable levels of anti-N, anti-S1, anti-RBD and anti-S2 IgG antibodies, but no anti-NTD antibodies (Figure 3A). However, for the non-hospitalized patients, the immune response appeared weaker, allowing to follow the IgG antibody different kinetics (Figure 3B). The number of patients with anti-N, anti-S1, anti-RBD and anti-S2 IgG antibodies, increased until 45 days post-PCR, before starting to drop, especially for anti-N IgG antibodies ($\Delta = -27.5\%$ between 31-45 and >45 days post-PCR). Furthermore in the 14 days following the PCR, the anti-N and anti-S2 are the main detected IgG antibodies (44.4% anti-N positives and 61.1% anti-S2 positives) while the anti-S1 IgG antibodies are generally detected latter (50% anti-S1 positives between 15-30 days).

Discussion

For routine diagnosis use, commercial serological assays must be evaluated in regard to their ability to detect early and weak infections. Several commercial assays have shown good performances focusing on the detection of total antibodies (IgG, IgM and IgA). However, as early diagnosis results are already delivered by PCR assays, serological assays detecting IgG seem more appropriate for the evaluation of an efficient and long lasting protection of the patients. Interestingly, the detection of antibodies against larger specter of antigens can also increase the diagnostic sensitivity, especially for generally weaker immune response of asymptomatic and mild forms. With diagnostic performances equivalent to other IgG commercial serological assays, the CoViDiag® multiplex assay gives a more comprehensive picture of

the IgG humoral response. This study investigates the profile of anti-SARS-CoV-2 different antibodies. We observed different pattern of IgG profiles between severe (hospitalized patients and PCR positives), mild (non-hospitalized patients and PCR positives), or asymptomatic (patients from the screening campaigns) form of the disease. On samples more than 45 days post-PCR, the percentage of different IgG positive results tends to decrease or remain constant for the mild and more severe form of the diseases, respectively. Furthermore, a lot of interrogations have been raised lately regarding the vaccination protocol for previously infected patients. As most vaccines are based on the RBD part of the S1 protein, multiplex serology has the potential to differentiate between infection and vaccination, and between variants, with a single assay. Future epidemical study on a larger panel of samples (especially extended to the population with mild or asymptomatic form of the disease), combining the multiplex assay with machine learning can be a convenient tool to investigate the kinetics and mechanisms of the immune response and contribute to the development of long lasting and efficient strategy of vaccination.

Funding

Laboratory's own resources

Declaration of Competing Interest

Authors Rémi Malbec, Gaël Even and Christophe Audebert are employees of GD Biotech, while Pauline Ponthieu, Pauline Follet, Vianney Souplet and Christophe Olivier are employees of Innobiochips, providing the CoViDiag[®] assay kits for this study.

References

1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020; 579: 270-273.
2. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *Journal of Medical Virology*. 2020; 92: 424-432.
3. Brochot E, Demey B, Touze A, Belouzard S, Dubuisson J, Schmit J-L, et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and asymptomatic carriers (*Infectious Diseases (except HIV/AIDS)*). 2020a.
4. Brochot E, Demey B, Handala L, François C, Duverlie G and Castelain S. Comparison of different serological assays for SARS-CoV-2 in real life. *J Clin Virol*. 2020b; 130: 104569.
5. Tuailon E. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. *MedRxiv*. 2020.
6. Krajewski R, Gołębiowska J, Makuch S, Mazur G and Agrawal S. Update on serologic testing in COVID-19. *Clin Chim Acta*. 2020; 510: 746-750.
7. Ota M. Will we see protection or reinfection in COVID-19? *Nature Reviews Immunology*. 2020; 20: 351-351.
8. de Assis RR, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero JM, et al. Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray (*Immunology*). 2020.
9. Coste AT, Jatou K, Papadimitriou-Olivgeris M, Greub G and Croxatto A. Comparison of SARS-CoV-2 serological tests with different antigen targets (*Infectious Diseases (except HIV/AIDS)*). 2020.
10. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity (*Infectious Diseases (except HIV/AIDS)*). 2020.